SCs, especially those that emerge following therapy or in specific tumor microenvironments, can upregulate core pluripotency factors including SOX2, OCT4, and NANOG (Swain et al., 2020; Chen and Wang, 2025; Hwang et al., 2025). This evidence concerns the gene NANOG and neoplasm.